Analyzing Edwards Lifesciences Corporation (EW) By Technical Indicators

As of Friday close, Edwards Lifesciences Corporation’s (NYSE:EW) stock was up $1.27, moving up 1.21 percent to $106.12. The average number of shares traded per day over the past five days has been 2,236,220 shares. 5 times new highs have been achieved over the past 5 days, with a $5.58 gain in that time frame. In the last twenty days, the average volume was 2,501,555, while in the previous 50 days, it was 2,620,094.

Since last month, EW stock rose 7.81%. Shares of the company fell to $93.80 on 07/13/22, the lowest level in the past month. A 52-week high of $131.73 was reached on 04/21/22 after having rallying from a 52-week low of $85.58. Since the beginning of this year, EW’s stock price has dropped by -18.09% or -$23.43, and marked a new high 3 times. However, the stock has declined by -19.44% since its 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Edwards Lifesciences Corporation (EW) last reported insider trading activity 1 day ago on Aug 05. Zovighian Bernard J, the CVP, TMTT of the company, disposed of 4,811 shares for $103.66 on Aug 05. It resulted in a $498,708 divestment by the insider. Chopra Daveen sold 1,000 shares at an average price of $102.49 on Aug 02. The insider now owns 18,911 shares following the transaction. On Jul 14, Chairman & CEO MUSSALLEM MICHAEL A sold 19,875 shares at $95.88 apiece. The transaction was valued at $1,905,626.

Valuation Metrics

Right now, Edwards Lifesciences Corporation (EW) has a P/E ratio of about 45.92. The stock’s beta is 1.16. Besides these, the trailing price-to-sales (P/S) ratio of 12.94, the price-to-book (PB) ratio of 11.29, and the price-to-cash flow ratio of 49.28 may also be considered.

Financial Health

In the three months ended June 29, Edwards Lifesciences Corporation’s quick ratio stood at 2.60, while its current ratio was 3.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.10, and the total debt-to-equity ratio was 0.10. On the profitability front, the trailing twelve-month gross margin is 77.80% percent. In the year ended June 29, operating margins totaled 31.60%. Based on annual data, EW earned $3.98 billion in gross profit and brought in $5.23 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 23.20%. Return on equity (ROE) for the past 12 months was 26.90%.

In Edwards Lifesciences Corporation’s quarter-end financial report for June 29, it reported total debt of $596.0 million against cash and short-term investments of $317.7 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. EW’s revenue fell -0.15% to $1.34 billion during the quarter, while net income inched up to $1.37 billion. While analysts expected Edwards Lifesciences Corporation to report $0.64 quarterly earnings, the actual figure was $0.63 per share, beating the consensus estimate by -1.60%. During the quarter, the company generated $493.6 million in EBITDA. The liabilities of Edwards Lifesciences Corporation were 2.48 billion at the end of its most recent quarter ended June 29, and its total debt was $682.8 million. The value of shareholders’ equity is $619.94 million.

Technical Picture

This quick technical analysis looks at Edwards Lifesciences Corporation’s (EW) price momentum. With a historical volatility rate of 43.40%, the RSI 9-day stood at 63.71% on 05 August.

With respect to its five-day moving average, the current Edwards Lifesciences Corporation price is up by +5.55% percent or $5.58. At present, EW shares trade +7.86% above its 20-day simple moving average and +3.78% percent above its 100-day simple moving average. However, the stock is currently trading approximately +12.25% above its SMA50 and -7.72% below its SMA200.

Stochastic coefficient K was 70.49% and Stochastic coefficient D was 62.04%, while ATR was 3.19. Given the Stochastic reading of 80.89% for the 14-day period, the RSI (14) reading has been calculated as 61.35%. As of today, the MACD Oscillator reading stands at 1.29, while the 14-day reading stands at 1.74.

Analyst Ratings

Edwards Lifesciences Corporation downgraded its rating on Edwards Lifesciences Corporation (NYSE: EW) to a Hold in a note to investors on July 29, 2022. The analysts firm previously had a Buy rating on the stock.Edwards Lifesciences Corporation (EW) has been rated Overweight by analysts. According to 0 brokerage firms, EW is a sell, and 6 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 2 analysts rate Edwards Lifesciences Corporation stock as buy, with 15 recommending it as overweight.

With a median target price of $119.00, the current consensus forecast for the stock is $97.00 – $135.00. Based on these forecasts, analysts predict Edwards Lifesciences Corporation (EW) will achieve an average price target of $117.37.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]